Coffee Talk: Charting New Pathways With HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate recent clinical trial evidence supporting TROP2- and HER2-directed antibody-drug conjugates (ADCs) for appropriate integration into metastatic breast cancer management
• Develop individualized treatment sequences incorporating TROP2- and HER2-directed ADC therapies based on biomarker and patient characteristics

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Chair:

Hope S. Rugo, MD, FASCO

Director, Women's Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF

Disclosures: Consulting or Advisory Role: BioNTech, Bristol Myers Squibb, Helsinn, Napo; Institutional research funding to prior institution, UCSF: Ambryx, AstraZeneca, Daiichi Sankyo, Inc., F. Hoffman-La Roche/Genentech, Gilead Sciences, Inc., Lilly, Merck & Co., Novartis Pharmaceuticals, Pfizer, Stemline Therapeutics; Institution research funding to current institution, City of Hope: Bicycle Therapeutics, F. Hoffman-La Roche/Genentech, Merck & Co., Stemline Therapeutics

Faculty:

Paolo Tarantino, MD, PhD

Clinical Fellow
Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Menarini/Stemline, Novartis, Roche; Grant/Research Funding: AstraZeneca

Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Olga Keith Wiess Chair of Surgery
Professor and Chief, Section of Breast Surgery
Co-Director, Lester and Sue Smith Breast Center
Leader, Breast Cancer Program
Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, TX

Disclosures: Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS, has no relevant financial relationships with ineligible companies.

Giuseppe Curigliano, MD, PhD

Professor of Medical Oncology
University of Milan
Director, Early Drug Development Division
European Institute of Oncology
Milan, Italy

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, BioNTech, Daiichi Sankyo, Exact Sciences, Lilly, Menarini, Merck, Novartis, Pfizer, Roche

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by an AI tool.

To learn more about this topic, including information on HER2- and TROP2-directed ADCs in the management of early-stage and advanced/metastatic breast cancer, go to https://www.gotoper.com/mbcc26coffeetalk-activity.

Release Date

April 7, 2026

Expiration Date

April 7, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.